A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

Exclusion Criteria

• - Have any contraindication for the OAD(s) that they use.
• - Have a known allergy or hypersensitivity to exenatide BID, exenatide QW, or excipients contained in these agents.
• - Have received chronic >14 consecutive days) systemic glucocorticoid therapy by oral, intravenous (IV), or intramuscular (IM) route or intra-articular steroid injection within 4 weeks prior to study start or are regularly treated with potent, inhaled steroids that are known to have a high rate of systemic absorption.
• - Have been treated with drugs that promote weight loss (for example, GLP-1 analogue, orlistat, sibutramine, phenylpropanolamine, or similar over-the-counter medications) within 90 days of study start.
• - Have been treated for >2 weeks with any of the following excluded medications within 90 days prior to study start:
• • Insulin
• • Dipeptidyl peptidase (DPP)-4 inhibitors (for example, sitagliptin or vildagliptin)
• • Pramlintide acetate
• • Drugs that directly affect gastrointestinal motility, including, but not limited to: Reglan® (metoclopramide), Propulsid® (cisapride), and chronic macrolide antibiotics.
• - Have had prior exposure to exenatide
• - Have previously completed or withdrawn from this study or any other study investigating exenatide BID or QW.
• - Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
• - Are currently enrolled in any other clinical study.